Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1995-06-07
1998-03-17
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
A61K 3156
Patent
active
057286884
ABSTRACT:
Sex steroid precursors such as dehydroepiandrosterone and dehydroepiandrosterone sulphate, and compounds converted in vivo to either of the foregoing, are utilized for the treatment of vaginal atrophy, hypogonadism, diminished libido, loss of collagen or connective tissues in the skin, and, in combination with an estrogen and/or progestin, for the treatment of menopause. The precursors may be formulated for percutaneous or transmucosal administration. Gels, solutions, lotions, creams, ointments and transdermal patches for the administration of these precursors are provided, as are certain pharmaceutical compositions and kits which can be used for the prevention and treatment of a wide variety of conditions related to decreased secretion of sex steroid precursors by the adrenals.
REFERENCES:
patent: 3472931 (1969-10-01), Stoughton
patent: 3551554 (1970-12-01), Herschler
patent: 3742951 (1973-07-01), Zaffaroni
patent: 3797494 (1974-03-01), Zaffaroni
patent: 3989816 (1976-11-01), Jagannath
patent: 4006218 (1977-02-01), Tibor
patent: 4213978 (1980-07-01), Bodor
patent: 4405616 (1983-09-01), Rajadhyaksha
patent: 4425339 (1984-01-01), Pitchford
patent: 4496556 (1985-01-01), Orentreich
patent: 4518595 (1985-05-01), Coleman
patent: 4542129 (1985-09-01), Orentreich
patent: 4568343 (1986-02-01), Leeper
patent: 4624665 (1986-11-01), Nuwayser
patent: 4666441 (1987-05-01), Andriola
patent: 4812447 (1989-03-01), Roberts
patent: 4835147 (1989-05-01), Roberts
patent: 4956355 (1990-09-01), Prendergast
patent: 4978532 (1990-12-01), El-Rashidy
patent: 5047244 (1991-09-01), Sanvordeker et al.
patent: 5051260 (1991-09-01), Chess
patent: 5064654 (1991-11-01), Berner
patent: 5071644 (1991-12-01), Viegas
patent: 5071657 (1991-12-01), Oloff
patent: 5116828 (1992-05-01), Miura et al.
patent: 5135480 (1992-08-01), Bannon
patent: 5154922 (1992-10-01), Govil
patent: 5162037 (1992-11-01), Whitson
patent: 5362720 (1994-11-01), Labrie
Batra, et al., J. Urol., 129(2):418-420 (1983).
Bayliss, et al., An Illustrated Dictionary of Dermatologic Syndromes, Parthenon Publ. Group, NY, 1994, p. 243.
Peillon, et al., Ann. Endo., 26(4):419-28 (1965).
Am. J. Nurs., 70:2634 (1970).
Li, et al., British J. of Cancer, 41:123-129 (1980).
Araki, Kuramu Medical Journal, 28:35-43 (1981).
Berne, et al., Physiology, C.V. Mosby Co., St. Louis (1983).
Biological Abstracts, 70:52322 (1980).
Labrie, et al., J. of Clinical Endo. & Metab, 82(8):2403-2409 (1997).
Labrie, et al., J. of Clinical Endo. & Metab, 82:(8)2396-2402 (1997).
Labrie, et al., "Signal Tranduction in Testicular Cells: Basic and Clinical Aspects, Ernst Schering Research Foundation QWOrkshop," Supplement 2, Ed. Hansson, Springer-Verlag, pp. 185-218 (1996).
Labrie, et al., Steroids, 62:148-158 (1997).
Labrie, et al., N.Y. Academy of Sciences, 774:16-28 (1995).
Labrie, et al., J. of Clinical Endo. & Metab, 82(10):1-7 (1997).
Luo, et al., Endocrinology, 138(8):3387-3394 (1997).
Labrie, et al., DHEA and Sex Steroids, Society for Endocrinology (1996).
Reynolds, "Martindale The Extra Pharmacopoeia" --Prasterone, 29th Edition (1989).
CA, 96:46434c (1982).
Beamer, et al., Cancer Research, 48:2788-2792 (1988).
Marslew, et al., Maturitas, 12:7-16 (1991).
Djerassi, et al., J. Org. Chem., 27:1112 (1962).
Edman, The Menopause, p.222 (1983).
Ringold, et al., J. Am. Chem. Soc., 78:816 (1956).
Wilson, et al., Williams Textbook of Endocr., pp. 1033-1048 (1992).
Forest, Andregens in Childhood (19):104-120 (1989).
Meunier, et al., Histological heterogeneity...treatment,pp. 293-301 (1980).
Mortola, Journal of Clinical Endo. and Metab. 71(3) (1990).
Bird, Clinical & Investigative Medicine 7(2):119-122 (1984).
Roberts, et al., Biological Role of DHEA (1990).
Belisle, et al., Journal of Clinical Endocrinology & Metabolism, 45(3) (1977).
Poulin, et al., Br. Cancer Res. Treat. 13:265-276 (1989).
Haning, Jr., et al., Journal of Clinical Endocrinology & Metabolism, 69 (5) (1989).
Abou-Gharbia, et al., J. Pharm. Sci. 73:1643-5 (1984).
Adams, Mol. Cell. Endo. 41:1-17 (1985).
Aloia, et al., Arch. INt. Med. 143:1700-1704 (1984).
Arad, et al., Arteriosclerosis 2:159-166 (1989).
Baran, et al., Calcif. Tissue Res. 26:103-106 (1978).
Belanger, et al., Annals of the NY Acad Sci. 586:93-100 (1990).
Brownsey, B.; Cameron, E. H. D.; Griffiths, K.; Gleave, E. N.; Forrest, A.P.M.; Campbell, H. (1972) Plasma dehydreopiandrosterone sulphate levels in patients with benign and malignant breast disease. Europ. J. Cancer. 8:131-137.
Bulbrook RD; Hayward JL; Spicer CC; Thomas BS (1962) Abnormal excretion of urinary steroids by women with early breast cancer. The Lancet. Dec.:1238-1240.
Bulbrook RD; Hayward JL; Spicer CC; Thomas CS (1962) A comparison between the urinary steroid excretion of normal women and women with advanced breast cancer. The Lancet. Dec.:1235-1240.
Bulbrook RD; Hayward JL; Spicer CC (1971) Relation between urinary androgen and corticoid excretion and subsequent breast cancer. The Lancet. Aug.:395-398.
Bundgard H (1991) Design and application of prodrugs. In: A textbook of drug design and development (P. Krogsgaard-Larsen, H. Bundgard, eds), Harwood Academic Publishers GmfH, Chur:Switzerland. pp.113-191.
Cameron EHD; Griffiths K; Gleave EN; Stewart HJ; Forrest APM; Campbell H (1970) Benign and malignant breast disease in south wales: a study of urinary steroids. Br. Med. J. 4:768-771.
Challis JRG; Heap RB (1970) Steroid mono- and diheptafluorobutyrates: preparation, purification and estimation. J. Chromatogr. 50:228-238.
Cleary MP; Zisk J (1983) Effect of dehydroepiandrosterone (DHEA) in adult zucker rats. Fed. Proc. 42:536 (abst. 1433).
Colevard DS; Eriksen EF; Keeting EM; Lubahn DB; French FS; Riggs BL; Spelsberg TC (1989) Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl. Acad Sci. USA. 86: 854-857.
Dauvois S; Geng CS; Levesque C; Merand Y;Labrie F (1991) Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res. 54:3131-3135.
Deutsch, S.; Benjamin, F.; Seltzer, V.; Tafreshi, M.; Kocheril, G.; Frank, A. (1987) The correlation of serum estrogens and androgens with bone density in the late postmenopause. Int. Gynecol. Obstet. 25:217-222.
Drefahl G (1982) Derivatisierung von dexran mit p-Amino-benzoesaure-androstenolonester. Z. Chem. 22:178.
Druzgala et al. (1991) J. Steriod Biochem. Molec. Biol. 38:149-154.
Edman CD (1983) Estrogen replacement therapy. In: The Menopause Springer Verlag: New York. 6:pp. 77-84.
Eriksen, E. F.; Colvard, D. S.; Berg, N.J.; Graham, M. L.; Mann, K. G.; Spelsbert, C.; Riggs, B.L. (1988) Evidence of estrogen receptors in normal human osterblast-like cells. Science. 241:84-86.
Finkelstein JS, Klibanski A; Neer RM; Greenspan SL; Rosenthal DI; Crowley WF (1987) Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann. Int. Med. 106:354-361.
Flood JF; Roberts E (1988) Dehydroepiandrosterone sulfate improves memory in aging mice. Brain Res. 448:178-181.
Friend DR (1990) Critical Reviews in Therapeutic Drug Carrier Systems. In: Transdermal delivery of contraceptives 7: pp. 149-186.
Furlaneto RW; Underwood LE; Van Wyk JJ (1977) Estimation of somatonmedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J. Clin. Invest 60:648-657.
Giusti G; Gonnelli P; Borrelli D; Fiorelli G; Forti G; Pazzagli M; Serio M (1975) Age-related secretion of androstenedione, testosterone and dihydrotestosterone by the human testis. Exp. Geront. 10:241-245.
Gomes, P.; Cassanas, G.; Halberg, F.; Hermida, R.; Robel, P.; Baulieu, E. E.; Lakatua, D.; Haus, E. (1988) Taux sanguinde sulfate de la dehydroepiandrosterone (DHEA-S) et risque de cancer du sein. C.R. Acad. Sci. Paris. t 306, serie III:261-264.
Gordon, G. B.; Bush, D E.; Weisman, H.F. (1988) Reduction of atherosclerosis by administration of dehydroepiandrosterone. J. Clin. Invest. 82:712-720.
Gordon, G. B.: Helzlsourer, K. J.; Comstock, G.W. (1991) Serum levels of dehydroepiandrosterone and its sulfate and the risk of developing bladder cancer. Cancer Res. 51:1366-1369
Endoreoherche, Inc.
Raymond Richard L.
LandOfFree
Therapeutic methods and delivery systems utilizing sex steroid p does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic methods and delivery systems utilizing sex steroid p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic methods and delivery systems utilizing sex steroid p will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-957725